^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | MK-2206 (AKT inhibitor) + D9 (TrxR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow
Published date:
07/16/2020
Excerpt:
Treatment of mice with disseminated ER+ human breast cancer showed that D9 plus MK-2206 blocked formation of new metastases more effectively than tamoxifen.
DOI:
10.1038/s41388-020-01391-z
